Melanoma Clinical Trials in Baltimore

Showing 301-320 of 320 trials

Phase II Trial of Allovectin-7® for Metastatic Melanoma

NCT00044356

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.

MelanomaMetastatic MelanomaMalignant Melanoma+1 more

Vical133 participantsStarted Feb 2001

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Bakersfield, California, United States +13 more locations

COMPLETEDPhase 2< 1 mile

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT00289640

The purpose of this clinical research study is to compare the best overall response rate (BORR)(as per modified WHO criteria) in patients with previously treated, therapy-refractory, or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg. The safety of this product will also be evaluated.

Melanoma

Bristol-Myers Squibb210 participantsStarted Apr 2006

Tucson, Arizona, United States • Laverne, California, United States • San Diego, California, United States +59 more locations

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma Trials in Other Cities

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Vaccine Therapy for Patients With Stage IV Melanoma

Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer

Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant

Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity

Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Efficacy Study of TLN-232 in Patients With Recurring Metastatic Melanoma

SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Study of XL281 in Adults With Solid Tumors

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

A Study of Volociximab in Metastatic Melanoma

Other Conditions in Baltimore